Your session is about to expire
← Back to Search
Phototherapy
UVA1 Phototherapy for Vitiligo
Phase 2
Waitlist Available
Led By Harvey Lui, MD, FRCPC
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age > 18 years
Localized or generalized vitiligo that involves a non-mucosal or acral site
Must not have
History of severe medical illness or immunosuppression
Patients known to have a photosensitivity disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial will test whether UVA1 phototherapy is an effective and safe treatment for vitiligo.
Who is the study for?
This trial is for adults over 18 with localized or generalized vitiligo, which isn't on mucosal or acral sites. They should have a patch of at least 25 cm2 with less than 10% repigmentation. It's not for those with severe illness, photosensitivity disorders, recent vitiligo treatments, history of skin cancer, or who are pregnant/breastfeeding.
What is being tested?
The study tests the effectiveness and safety of UVA1 phototherapy in treating vitiligo. This prospective single-blind randomized clinical trial compares patient outcomes to see how well UVA1 can improve the condition compared to other treatments.
What are the potential side effects?
While specific side effects aren't listed here, UVA1 therapy may cause skin irritation or increase sensitivity to sunlight. Long-term exposure could potentially raise risks for skin aging or cancer; however, these risks need further clarification within this context.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am older than 18 years.
Select...
I have vitiligo on areas of my skin that are not mucous membranes or on my hands and feet.
Select...
I have a skin area of at least 25 cm2 with less than 10% color return.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a history of serious illness or a weak immune system.
Select...
I have a condition that makes my skin extra sensitive to sunlight.
Select...
I have had skin cancer in the past.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: No treatment (covered)Active Control1 Intervention
Group II: UVA1Active Control1 Intervention
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,461 Previous Clinical Trials
2,485,182 Total Patients Enrolled
4 Trials studying Vitiligo
109 Patients Enrolled for Vitiligo
Harvey Lui, MD, FRCPCPrincipal InvestigatorUniversity of British Columbia
3 Previous Clinical Trials
64 Total Patients Enrolled
3 Trials studying Vitiligo
64 Patients Enrolled for Vitiligo
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have vitiligo on areas of my skin that are not mucous membranes or on my hands and feet.I have a history of serious illness or a weak immune system.I am older than 18 years.I have a skin area of at least 25 cm2 with less than 10% color return.I have a condition that makes my skin extra sensitive to sunlight.I have not treated my vitiligo in the last 3 weeks.I have had skin cancer in the past.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Research Study Groups:
This trial has the following groups:- Group 1: No treatment (covered)
- Group 2: UVA1
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Share this study with friends
Copy Link
Messenger